|
Molecules and Cells
Journal Prestige (SJR): 1.493  Citation Impact (citeScore): 3 Number of Followers: 1  Hybrid journal (It can contain Open Access articles)ISSN (Print) 0219-1032 - ISSN (Online) 1016-8478 Published by Springer-Verlag  [2469 journals]
|
- Are the Same Medications that Are Used in the Acute Treatment of
Depression the Most Suitable for Preventing Relapse'-
Free pre-print version: Loading...
Authors: Fava; Giovanni A.
Abstract: No abstract available
PubDate: Mon, 01 Nov 2021 00:00:00 GMT-
-
- How Homogeneous Are Diagnostic Groups'
-
Free pre-print version: Loading...
Authors: Shader; Richard I.; Streiner, David L.
Abstract: No abstract available
PubDate: Mon, 01 Nov 2021 00:00:00 GMT-
-
- Journal of Clinical Psychopharmacology Updates
-
Free pre-print version: Loading...
Authors: Rothschild; Anthony J.
Abstract: No abstract available
PubDate: Mon, 01 Nov 2021 00:00:00 GMT-
-
- Lifetime Cannabis Use Disorder Is Not Associated With Lifetime Impulsive
Behavior and Severe Violence in Patients With Schizophrenia Spectrum
Disorders From a High-Security Hospital-
Free pre-print version: Loading...
Authors: Comai; Stefano; Fuamba, Yves; Rivolta, Maria Chiara; Gobbi, Gabriella
Abstract:
Purpose/Background The link between substances of abuse, impulsivity, and violence in psychotic patients remains unclear. This study aims at unraveling whether cannabis use disorder is associated with violent and/or psychotic behavior in patients who are hospitalized in a high-security hospital.Methods/Procedures We conducted a cross-sectional retrospective study in 124 patients with schizophrenia spectrum disorders admitted to a high-security hospital. Lifetime violent behavior was assessed using the History of Aggressive Behavior Form-Subject of the MacArthur Violence Risk Assessment Study and impulsivity using the Psychopathy Checklist–Revised (considering items: “proneness to boredom,” “lack of self-control,” and “impulsive thoughtless gestures”). Substance use disorder was diagnosed according to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition criteria. Positive and Negative Syndrome Scale was also administered.Findings/Results Violent and nonviolent psychotic patients showed similar prevalence of cannabis use disorder. Alcohol and cocaine use disorders were more prevalent among violent psychotic patients. Cannabis use disorder was not associated with any dimension of impulsivity, whereas alcohol use disorder was positively correlated to impulsive thoughtless gestures (standardized β = 0.213, P = 0.027) and cocaine use disorder with proneness to boredom (standardized β = 0.290, P = 0.002). Finally, logistic regression analysis revealed that, unlike cannabis and cocaine use disorders, alcohol use disorder (odds ratio, 3.964; 95% confidence interval, 1.729–9.087; P = 0.001) was a factor associated with violence.Implications/Conclusions These findings show that cannabis and alcohol are largely abused and coabused by psychotic patients with a propsensity for violence, but only alcohol is associated with impulsive and violent behavior. Therefore, especially alcohol abuse should be seriously considered by practitioners when evaluating the dangerousness of patients with schizophrenia spectrum disorders.
PubDate: Mon, 01 Nov 2021 00:00:00 GMT-
-
- A Double-Blind, Placebo-Controlled Trial of Bupropion Add-on to Olanzapine
or Risperidone in Overweight Individuals With Schizophrenia-
Free pre-print version: Loading...
Authors: Weizman; Shira; Shelef, Assaf; Bloemhof Bris, Esther; Stryjer, Rafael
Abstract:
Background Weight gain due to antipsychotics is a challenging clinical problem because, to date, no effective pharmacological strategies have been found. Bupropion is often used in people with schizophrenia for smoking cessation and is well tolerated. However, studies on its use as weight loss treatment are scarce. The aim of the study was to examine the effectiveness of bupropion as a single weight loss treatment in overweight individuals maintained on long-term olanzapine or risperidone.Methods This randomized, double-blind, placebo-controlled, 8-week study included 26 overweight (body mass index ≥27 kg/m2) individuals with schizophrenia maintained on olanzapine (10–20 mg/d) or risperidone (2–4 mg/d). Participants were randomly allocated to a study group that received bupropion (150–300 mg/d) or to a placebo group. The positive and Negative Syndrome Scale and the Clinical Global Impression–Severity Scale were used to assess severity of psychosis at baseline and end of study (8 weeks).Results Bupropion addition, but not placebo, was associated with a significant reduction in body weight. Severity of psychotic symptoms was not altered in either group.Conclusions The results demonstrate the efficacy of bupropion, compared with placebo, in patients maintained on chronic treatment with olanzapine or risperidone, both known to be major contributors to significant weight gain.
PubDate: Mon, 01 Nov 2021 00:00:00 GMT-
-
- Effect of Miricorilant, a Selective Glucocorticoid Receptor Modulator, on
Olanzapine-Associated Weight Gain in Healthy Subjects: A Proof-of-Concept
Study-
Free pre-print version: Loading...
Authors: Hunt; Hazel J.; Donaldson, Kirsteen; Strem, Mark; Tudor, Iulia Cristina; Sweet-Smith, Suzanne; Sidhu, Sharan
Abstract:
Purpose Antipsychotic medications, including olanzapine, are associated with substantial weight gain and metabolic disturbances. We sought to determine whether coadministration of miricorilant, a selective glucocorticoid receptor modulator, with olanzapine can ameliorate these effects.Methods Sixty-six healthy men were enrolled in a 2-week, randomized, double-blind, placebo-controlled trial. The primary objective was to evaluate changes in body weight after 14 days coadministration of olanzapine (10 mg) + miricorilant (600 mg) compared with olanzapine (10 mg) + placebo. Secondary objectives included evaluating (a) the safety and tolerability of the combination; (b) the effects of the combination on glucose, insulin, insulin resistance, and triglycerides; and (c) the impact of the combination on hepatic enzymes.Results Subjects administered olanzapine + miricorilant gained less weight than subjects administered olanzapine + placebo (mean weight gain on day 15, 3.91 kg vs 4.98 kg; difference between groups, −1.07 kg; 95% confidence interval, −1.94 to −0.19; P = 0.017]). Compared with the placebo group, coadministration of miricorilant with olanzapine was associated with smaller increases in insulin (difference, −3.74 mIU/L; P = 0.007), homeostatic model assessment of insulin resistance (difference, −0.47; P = 0.007), triglycerides (difference, −0.29 mmol/L; P = 0.057), aspartate aminotransferase (difference, −32.24 IU/L; P = 0.009), and alanine aminotransferase (difference, −49.99 IU/L; P = 0.030).Conclusions Miricorilant may provide a promising option for ameliorating the detrimental effects of olanzapine, and investigation of this medication in patients affected by antipsychotic-induced weight gain is warranted. Two phase 2 studies of miricorilant in patients with recent and long-standing antipsychotic-induced weight gain are currently in progress.
PubDate: Mon, 01 Nov 2021 00:00:00 GMT-
-
- Improvements of Frontotemporal Cerebral Blood Flow and Cognitive
Functioning in Patients With First Episode of Schizophrenia Treated With
Long-Acting Aripiprazole-
Free pre-print version: Loading...
Authors: Peitl; Vjekoslav; Badžim, Vivian A.; Šiško Markoš, Ines; Rendulić, Ana; Matešić, Krunoslav; Karlović, Dalibor
Abstract:
Purpose/Background Frontal and temporal cerebral blood flow (CBF) changes are the most common impairments of CBF described in patients with schizophrenia. Those impairments have also been associated with cognitive deficits, a hallmark of schizophrenia. In light of that fact, treatment interventions should target cognitive deficits to prevent chronic disability. However, specific therapies targeting cognitive symptoms are very few and far between. One of the treatment possibilities is aripiprazole, because several studies reported its potential procognitive effects. The objective of this study was to investigate whether use of aripiprazole in its long-acting injectable formulation (ALAI), during a 3-month treatment, has beneficial effects on CBF and cognitive functioning in patients with first episode of schizophrenia.Methods/Procedures Single-photon emission computed tomography with technetium-99m hexamethylpropylene amine oxime was performed at 2 time points. Cognitive functions were assessed with a standardized test for cognitive functions, 5-KOG test, whereas severity of clinical symptoms was assessed with the Positive and Negative Syndrome Scale, both at the same 2 time points as single-photon emission computed tomography. Three-month treatment with ALAI was associated with improvement of several cognition indices and improvements of right-sided frontal and temporal CBF, as well as of clinical symptoms.Findings/Results Multivariate tests were used to test for the effects of ALAI treatment on cognitive functions, clinical presentation, and brain perfusion in a 3-month period. Multivariate model revealed statistical significance (F = 11.958, P < 0.001). Of 10 separate 5-KOG parameters, 3-month treatment with ALAI significantly influenced 4: undelayed recall, delayed recall, attention, and working memory—digit span forward. Finally, 3-month ALAI treatment significantly improved regional CBF in 2 of 4 investigated areas, both on the right side of the brain (frontally and temporally).Implications/Conclusions Results of this research showed that treatment with ALAI in patients with first episode of schizophrenia is associated with improved right-sided frontal and temporal CBF, as well as with improved symptoms, including cognition indices. Although we cannot confirm it directly, it is possible that improved frontotemporal CBF led to the improvement in cognition indices.
PubDate: Mon, 01 Nov 2021 00:00:00 GMT-
-
- The Effect of Adding Memantine to Clonidine in Reducing Withdrawal
Symptoms in Opioid-Dependent Patients: A Double-Blind Randomized
Controlled Trial-
Free pre-print version: Loading...
Authors: Kheirabadi; Gholamreza; Najafian, Narges; Khodadadi, Farinaz
Abstract:
Objective Addiction is a complex condition and a brain disease manifested by compulsive substance use despite its harmful consequence. Addicted individuals have an intense focus on using substances. This study aimed to investigate the effect of adding memantine to clonidine and buprenorphine in reducing withdrawal symptoms, compared with placebo, in drug-dependent patients (opium and heroin).Materials and Methods In this double-blind, randomized clinical trial study, 60 patients using opium or heroin were assigned to the intervention (n = 30) and control (n = 30) groups. Both groups were treated with buprenorphine and clonidine at the same dose in the detoxification process. The intervention group received memantine 10 mg daily for 10 days and then 20 mg daily for 21 days, and the control group received a placebo prepared in the same shape and size as memantine tablets. The severity of withdrawal symptoms was measured using the Short Opioid Withdrawal Scale over 3 weeks. Data analysis was performed using SPSS and descriptive and inferential tests.Results The results showed that despite memantine's superiority in controlling some withdrawal symptoms such as feeling sick, stomach pain, muscle spasm, and feeling cold, no significant difference was found between the 2 groups. There was also no statistically significant difference between the 2 groups in the total score of symptoms.Conclusions No specific advantage of memantine was found for reducing the symptoms of withdrawal syndrome in the present study. However, this drug was well tolerated without any evidence of serious or significant adverse effects.
PubDate: Mon, 01 Nov 2021 00:00:00 GMT-
-
- Antipsychotic-Related Fatal Poisoning, England and Wales, 1993–2019: The
Impact of Second-Generation Antipsychotics-
Free pre-print version: Loading...
Authors: Handley; Simon Alfred; Every-Palmer, Susanna; Flanagan, Robert James
Abstract:
Background Deaths from antipsychotic (AP) poisoning have increased in England and Wales despite restriction of the use of thioridazine in 2000.Methods We analyzed data from the Office for National Statistics drug-related death database, England and Wales, 1993–2019, to investigate fatal AP poisoning.Results There were 2286 deaths (62% male patients). Annual numbers of intentional AP-related fatal poisonings (suicides) were relatively stable (1993, 35; 2019, 44; median, 44; range, 30–60). Intentional overdose deaths involving clozapine (96 male, 25 female) increased from 1 in 1994 to 5 in 2003 and have since remained relatively constant (median, 6; range, 3–10 per annum). Unintentional second-generation AP-related fatal poisonings have increased steadily since 1998, featuring in 828 (74%) of all unintentional, AP-related fatal poisonings in the period studied (2019, 89%). There were 181 unintentional clozapine-related deaths, (107 [59%] alone without other drugs ± alcohol) as compared with 291 quetiapine-related deaths (86 [30%] alone without other drugs ± alcohol) and 314 unintentional olanzapine-related deaths (77 [25%] alone without other drugs ± alcohol). Some 75% of all unintentional clozapine- and olanzapine-related deaths were of male patients (78% and 73%, respectively) as compared with 58% of unintentional quetiapine-related fatal poisonings. Clozapine now features prominently in intentional and in unintentional AP-related fatal poisoning in England and Wales. Deaths of male patients predominate in both categories. There were also 77 and 86 deaths attributed to unintentional poisoning with olanzapine and with quetiapine, respectively, in the absence of other drugs.Conclusions More effort is needed to prevent unintentional deaths not only from clozapine but also from olanzapine and quetiapine.
PubDate: Mon, 01 Nov 2021 00:00:00 GMT-
-
- Olanzapine-Related Somnambulism: A Systematic Review of Literature and a
Case Report of Anorexia Nervosa-
Free pre-print version: Loading...
Authors: de Filippis; Renato; Guinart, Daniel; Rania, Marianna; Carbone, Elvira Anna; Gaetano, Raffaele; Segura-Garcia, Cristina
Abstract:
Background Somnambulism, or sleepwalking (SW), is one of the most common forms of arousal parasomnias. It is characterized by different complex motor behaviors leading to unwanted movements in bed or walking during sleep. It can be the consequence of psychological stress, abnormal breathing during sleep, high fever, or drug adverse effects. There is evidence of an association between antipsychotic treatment, including olanzapine, and SW.Methods We present the case of a patient experiencing treatment-resistant anorexia nervosa whose somnambulism re-exacerbated after the addition of a low dose of olanzapine, following the CARE (CAse REport) Statement and Checklist. We also conducted a systematic review of the literature on olanzapine-induced somnambulism following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. PubMed, PsychINFO, and the Cochrane Library databases were independently reviewed up to January 2021 for articles reporting olanzapine-related somnambulism cases, without language or time restriction.Results We describe a case of somnambulism in a patient initially admitted to our hospital for anorexia nervosa and treated with a low dose of olanzapine. This is the first case of SW induced by olanzapine in eating disorders to be reported. Up-to-date olanzapine-related somnambulism was described in 8 patients experiencing psychiatric disorders (ie, schizophrenia and bipolar disorder).Conclusions To provide a reliable estimate of incidence and prevalence for olanzapine-related somnambulism, large-scale, pharmacovigilance studies are required, to allow for comparisons of overall clinical characteristics, outcomes, including time to recovery, between different treatment options. Clinician awareness should be enhanced, and attention should be given to such infrequent adverse effects associated with antipsychotics.
PubDate: Mon, 01 Nov 2021 00:00:00 GMT-
-
- CYP2D6 Genotyping and Antipsychotic-Associated Extrapyramidal Adverse
Effects in a Randomized Trial of Aripiprazole Versus Quetiapine Extended
Release in Children and Adolescents, Aged 12–17 Years, With First
Episode Psychosis-
Free pre-print version: Loading...
Authors: Rudå; Ditte; Jensen, Karsten Gjessing; Decara, Marie Stentebjerg; Klauber, Dea Gowers; Fagerlund, Birgitte; Møllegaard, Jens Richardt; Linnet, Kristian; Werge, Thomas; Correll, Christoph U.; Fink-Jensen, Anders; Jürgens, Gesche; Pagsberg, Anne Katrine
Abstract:
Purpose/Background The aim of this study was to examine the association between genetically predicted CYP2D6 phenotypes and extrapyramidal symptoms (EPSs).Methods/Procedures Data from the Tolerability and Efficacy of Antipsychotics trial of adolescents with first-episode psychosis randomized to aripiprazole versus quetiapine extended release were studied. Extrapyramidal symptom assessments included the Simpson-Angus Scale and the Barnes Akathisia Rating Scale. Patients were CYP2D6 genotyped. Plasma concentrations of antipsychotics and antidepressants were analyzed.Findings/Results One hundred thirteen youths (age, 12–17 years; males, 30%; antipsychotic naive, 51%) were enrolled. Poor metabolizers had a significantly higher dose-adjusted aripiprazole plasma concentration (±SD) compared with normal metabolizers at week 4 (24.30 ± 6.40 ng/mL per milligram vs 14.85 ± 6.15 ng/mL per milligram; P = 0.019), but not at week 12 (22.15 ± 11.04 ng/mL per milligram vs 14.32 ± 4.52 ng/mL per milligram; P = 0.067). This association was not found in the quetiapine extended release group. No association between CYP2D6 genotype groups and global Barnes Akathisia Rating Scale score or Simpson-Angus Scale score was found in any of the treatment arms.Implications/Conclusions Our results do not support routine use of CYP2D6 testing as a predictor of drug-induced parkinsonism or akathisia risk in clinical settings. Further studies with larger samples of CYP2D6 poor metabolizers are needed.
PubDate: Mon, 01 Nov 2021 00:00:00 GMT-
-
- Can Quetiapine Prolong the Antidepressant Effect of Ketamine': A
5-Year Follow-up Study-
Free pre-print version: Loading...
Authors: Amiaz; Revital; Saporta, Rachel; Noy, Adam; Berkenstadt, Haim; Weiser, Mark
Abstract:
Purpose Ketamine, a noncompetitive, high-affinity antagonist of the N-methyl-d-aspartate-type glutamate receptor, has a rapid effect in patients with treatment-resistant disorder, but many patients who respond to intravenous ketamine relapse within several days. The objective of this study was to examine the long-term outcome of patients' mood 5 years after ketamine treatment.Methods Sixteen electroconvulsive therapy referrals received at least 1 intravenous ketamine treatment in addition to their stable antidepressant medications. Depression was evaluated using the Inventory of Depressive Symptomatology–Clinician-Rated, Hamilton Rating Scales for Depression, and Montgomery-Åsberg Depression Rating Scale. Anxiety was measured using the Hamilton Rating Scale.Results Of 16 patients treated, 6 achieved complete remission, 3 partially responded, and 7 did not respond. At baseline, all patients were treated with antidepressants, 14 patients were also treated with neuroleptics, of whom 5 patients were treated with quetiapine. The time to relapse in the 5 patients taking quetiapine was significantly longer than in patients who were taking other neuroleptics (965.83 ± 824.68 vs 80.5 ± 114.3, Z = 7.001, P = 0.0001). At the 5-year follow-up, 3 of the patients taking quetiapine maintained their remission. Overall levels of depression and anxiety at all times were improved in comparison to baseline.Conclusions Our follow-up results suggest that the combination of quetiapine and ketamine can prolong time to relapse after ketamine treatment in patients with treatment-resistant disorder.
PubDate: Mon, 01 Nov 2021 00:00:00 GMT-
-
- Olanzapine Reduction From High Dose to Standard Dose: A Retrospective
Chart Review-
Free pre-print version: Loading...
Authors: Okeya; Komugi; Misawa, Fuminari; Fujii, Yasuo; Takeuchi, Hiroyoshi
Abstract:
Purpose/Background Although high-dose olanzapine might be a treatment option in patients with treatment-resistant schizophrenia, it can be reduced to the standard dose after symptoms are stabilized. We examined the rate of olanzapine reduction from high to standard dose and whether this change was successful.Methods/Procedures We included patients who received high-dose olanzapine (>20 mg/d) for 4 weeks or longer at our hospital. First, we retrospectively followed the patients for 6 years and estimated the percentage of those whose olanzapine was reduced from high to standard dose. Second, we followed patients who received olanzapine reduction for 1 year and estimated the rate of success based on the study-defined criteria for unsuccessful reduction. We also explored factors associated with the dose reduction and successful results.Findings/Results Among 110 patients who received high-dose olanzapine treatment, 72 had their olanzapine dose reduced to the standard dose for 6 years; the duration of high-dose olanzapine treatment was significantly and negatively associated with a reduction in olanzapine (hazard ratio, 0.98; 95% confidence interval, 0.98–0.99). Among the patients whose olanzapine was reduced, 50 achieved successful reduction for 1 year. Among the reasons for the reduction, an unknown reason was significantly associated with successful reduction (hazard ratio, 4.93; 95% confidence interval, 1.55–22.8).Implications/Conclusions The findings suggest that high-dose olanzapine can be reduced to the standard dose after stabilization of symptoms in most patients with schizophrenia.
PubDate: Mon, 01 Nov 2021 00:00:00 GMT-
-
- Association of Optimal Lamotrigine Serum Levels and Therapeutic Efficacy
in Mood Disorders: A Systematic Review-
Free pre-print version: Loading...
Authors: Kumar; Rakesh; Nuñez, Nicolas A.; Prokop, Larry J.; Veldic, Marin; Betcher, Hannah; Singh, Balwinder
Abstract:
Purpose The aim of the study was to appraise the current evidence on the optimal serum level for lamotrigine (LAM) in the treatment of mood disorders (major depressive disorder, bipolar disorder).Methods Major databases were searched for randomized controlled trials, open-label trials, and observational studies reporting serum LAM levels in adult patients treated with LAM for mood disorders.Results A total of 814 abstracts were screened and 24 articles were selected for full-text review. Seven studies (226 bipolar disorder and 17 major depressive disorder patients) including 1 randomized controlled trial (n = 43), 3 prospective (n = 53), and 3 retrospective (n = 147) studies met the study criteria with a study duration range from 6 to 96 weeks. Lamotrigine daily dosage varied from 25 to 425 mg/d among the studies. Studies reported inconsistent findings between LAM concentration and efficacy. Three studies did not identify a relationship between LAM levels and a significant improvement in mood symptoms. Two studies (n = 99) reported higher response rates with LAM serum levels of greater than 3.25 μg/mL and 1 study (n = 25) reported a wide therapeutic window of 5 to 11 μg/mL. Overall, LAM was well tolerated with no major significant adverse effects.Conclusions Most studies showed a minimum LAM threshold level of 3 μg/mL in patients with mood disorders; however, the data are inconsistent regarding the therapeutic range for LAM. Based on the pooled data, there is inconsistent evidence to make conclusive recommendations on therapeutic LAM serum levels for mood improvement. Further studies including larger sample sizes are required to address this relevant clinical question.
PubDate: Mon, 01 Nov 2021 00:00:00 GMT-
-
- Further Studies of Effects of Finasteride on Mood and Suicidal Risk
-
Free pre-print version: Loading...
Authors: Baldessarini; Ross J.; Pompili, Maurizio
Abstract:
No abstract available
PubDate: Mon, 01 Nov 2021 00:00:00 GMT-
-
- A Seizure After COVID-19 Vaccination in a Patient on Clozapine
-
Free pre-print version: Loading...
Authors: Makhlouf; Ahmed T.; Van Alphen, Manjola U.; Manzano, Giovanna S.; Freudenreich, Oliver
Abstract: No abstract available
PubDate: Mon, 01 Nov 2021 00:00:00 GMT-
-
- Grapefruit Juice Cleanse Mimicking Quetiapine Overdose: Case Report and
Review of Literature-
Free pre-print version: Loading...
Authors: Cinderella; Margaret A.; Morell, Benjamin; Munjal, Sahil
Abstract:
No abstract available
PubDate: Mon, 01 Nov 2021 00:00:00 GMT-
-
- Tardive Myoclonus Responsive to Clozapine Misdiagnosed as Restless Leg
Syndrome: A Case Report-
Free pre-print version: Loading...
Authors: Selçuk; Mahmut
Abstract: No abstract available
PubDate: Mon, 01 Nov 2021 00:00:00 GMT-
-
- Switch to 3-Month Long-Acting Injectable Paliperidone May Decrease Plasma
Levels: A Case Series-
Free pre-print version: Loading...
Authors: Cellini; Lorenzo; De Donatis, Domenico; Mercolini, Laura; Panariello, Fabio; De Ronchi, Diana; Serretti, Alessandro; Conca, Andreas; Gaspari, Davide; Giupponi, Giancarlo; Zernig, Gerald; Florio, Vincenzo
Abstract:
No abstract available
PubDate: Mon, 01 Nov 2021 00:00:00 GMT-
-
- Donepezil and Inappropriate Sexual Behavior in a Patient With Vascular
Dementia and on Bupropion: A Case Report-
Free pre-print version: Loading...
Authors: Haghani Tehrani; Poonè; Kohli, Kanchan K.; Khafaja, Mohamad H.
Abstract: No abstract available
PubDate: Mon, 01 Nov 2021 00:00:00 GMT-
-
- Chasing the Offending Medication: When Antidepressants Lead to
Hypoglycemia-
Free pre-print version: Loading...
Authors: Singh; Nirmal; Khetan, Aditya; Gupta, Rishab
Abstract: No abstract available
PubDate: Mon, 01 Nov 2021 00:00:00 GMT-
-
- Author Index 2021
-
Free pre-print version: Loading...
Abstract: No abstract available
PubDate: Mon, 01 Nov 2021 00:00:00 GMT-
-
- Subject Index 2021
-
Free pre-print version: Loading...
Abstract: No abstract available
PubDate: Mon, 01 Nov 2021 00:00:00 GMT-
-
